Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression

Código QR

Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression

Yu Zhang,1,2,&ast; Xin Zhang,3,&ast; Zhuoyi Jin,2 Huiyan Chen,4 Chenjing Zhang,2 wangyue Wang,2 Jiyong Jing,5 Wensheng Pan1,2 1Department of Clinical Medicine, Medical College of Soochow University, Suzhou, 215006, People’s Republic of China; 2Department of Gastroenterology, Zhejiang Provinc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang Y, Zhang X, Jin Z, Chen H, Zhang C, Wang W, Jing J, Pan W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	adenoma-carcinoma immune environment pd-1/pd-l1 tumor-infiltrating lymphocytes xrcc1 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6c3f244103304cd782f9f04de268c163
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

DNA Repair Genes XRCC1, XRCC3, XPD, and OGG1 Polymorphisms among the Central Region Population of Saudi Arabia
por: Alanazi,Mohammad, et al.
Publicado: (2013)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Gaurav Garg, et al.
Publicado: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai CY, et al.
Publicado: (2021)

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers
por: Yasuhito Mihashi, et al.
Publicado: (2021)

X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone –induced apoptosis in pancreatic cancer cells
por: Yansong Zheng, et al.
Publicado: (2021)

Decreased T Cell Levels in Critically Ill Coronavirus Patients: Single-Center, Prospective and Observational Study
por: Xu J, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
por: Xiangdong Ye, et al.
Publicado: (2021)

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: Dina Mohamed El Samman, et al.
Publicado: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Yixi Zhang, et al.
Publicado: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)

New Insights into the Role of PD-1 and Its Ligands in Allergic Disease
por: Miguel Angel Galván Morales, et al.
Publicado: (2021)

Applicability and interpretation of HER2/Neu & PD-L1 stains in gastrointestinal tract tumours
por: Prasenjit Das, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Otgontuya Ganbaatar, et al.
Publicado: (2021)

Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy
por: Mei J, et al.
Publicado: (2021)

Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
por: Kurtis M. Host, et al.
Publicado: (2017)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
por: Luo M, et al.
Publicado: (2021)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
por: Luo M, et al.
Publicado: (2021)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
por: Chang-Jin Jung, et al.
Publicado: (2021)

Adenoma negro de la glándula suprarrenal (Black Adenoma)
por: Castillo C,Octavio A, et al.
Publicado: (2013)

Association between XRCC1 exon 10 (Arg399Gln) gene polymorphism and micronucleus as a predictor of DNA damage among radiation workers
por: HARRY NUGROHO EKO SURNIYANTORO, et al.
Publicado: (2018)

Establishment and Verification of Scoring System for Colorectal Adenoma Recurrence
por: Xi X, et al.
Publicado: (2021)

High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury
por: Dong L, et al.
Publicado: (2021)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Laura Jimbu, et al.
Publicado: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
por: Olga V. Kovaleva, et al.
Publicado: (2021)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Sara Bravaccini, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
por: Christina Polasky, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Myeong Joon Kim, et al.
Publicado: (2021)

YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1
por: Mingran Zhang, et al.
Publicado: (2021)

Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
por: R. V. Orlova, et al.
Publicado: (2021)

Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy
por: Kerstin Skibbe, et al.
Publicado: (2021)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Virginia Liberini, et al.
Publicado: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Peiyi Xie, et al.
Publicado: (2021)

Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density
por: Xu Y, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis
por: Minsuk Kim, et al.
Publicado: (2020)